Adding empasiprubart to IVIg for Guillain-Barré syndrome
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new investigational medicine called empasiprubart when added to the standard IVIg treatment for people with Guillain-Barré syndrome. It aims to see if adding this medicine can help improve recovery compared to IVIg alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with typical Guillain-Barré syndrome (GBS) by a doctor.
- Your GBS muscle weakness started within the last 7 days before the first treatment in this study.
- Your GBS is severe enough that you need help walking or cannot walk at all (score of 3, 4, or 5 on a 0–6 scale).
- Before GBS, you were able to walk about 10 meters (the length of a bus) without assistance.
- You agree to take antibiotics to prevent certain bacterial infections for the first 90 days of the study or to complete a vaccination schedule.
- You have not previously had GBS, do not have lupus or a complement deficiency, and have no other serious medical conditions that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called efgartigimod for people with Guillain-Barré syndrome (GBS), a condition where the immune system attacks the nerves. The medicine aims to reduce the immune attack and help you recover faster. It is for people who started having GBS symptoms within the last 2 weeks and have moderate to severe symptoms.
This is an observational study that looks at people who were suspected to have Guillain-Barré syndrome and were cared for at University Hospital of Basel in the past. It does not test a new treatment—researchers review existing care to learn more about this condition.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This trial tests whether an experimental drug called efgartigimod (given as an infusion) can help people with Guillain-Barré syndrome recover faster. It is for adults who recently developed symptoms and have significant weakness that affects their walking.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
Hear when a new Guillain-Barré Syndrome (GBS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.